Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$11.62 -2.8%	$11.78	$4.88 ▼ $19.58	$252.11M	N/A	82,020 shs	71,052 shs
MNPR Monopar Therapeutics	$46.48 -1.6%	$35.86	$1.72 ▼ $54.30	$284.23M	1.01	363,996 shs	30,457 shs
RPTX Repare Therapeutics	$1.51 -0.7%	$1.42	$0.89 ▼ $4.22	$64.77M	0.84	293,370 shs	319,262 shs
TSVT 2seventy bio	$5.00	$5.00	$2.29 ▼ $5.30	$266.15M	1.04	646,255 shs	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	-4.52%	-3.81%	+66.00%	+1,161,999,900.00%
MNPR Monopar Therapeutics	0.00%	+26.06%	+40.85%	+17.40%	+1,209.30%
RPTX Repare Therapeutics	0.00%	+0.67%	+7.09%	+25.83%	-58.97%
TSVT 2seventy bio	0.00%	0.00%	0.00%	+0.40%	+4.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	2.4568 of 5 stars	3.4	2.0	0.0	0.0	3.0	2.5	0.0
RPTX Repare Therapeutics	2.8128 of 5 stars	3.3	3.0	0.0	0.0	2.4	2.5	0.6
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$33.00	183.99% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	29.09% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	198.01% Upside
TSVT 2seventy bio	2.00	Hold	$5.00	N/A

Current Analyst Ratings Breakdown

Latest RPTX, MNPR, TSVT, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/30/2025	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/15/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/10/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
4/24/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A
RPTX Repare Therapeutics	$53.48M	1.21	N/A	N/A	$3.56 per share	0.42
TSVT 2seventy bio	$48.37M	5.50	N/A	N/A	$5.04 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$20.59M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	8/8/2025 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$3.01	N/A	N/A	N/A	N/A	-78.12%	-67.11%	8/5/2025 (Estimated)
TSVT 2seventy bio	-$217.57M	-$0.10	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	8/6/2025 (Estimated)

Latest RPTX, MNPR, TSVT, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	N/A	MNPR Monopar Therapeutics	-$0.47	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	TSVT 2seventy bio	-$0.05	N/A	N/A	N/A	$15.45 million	N/A
8/5/2025	Q2 2025	RPTX Repare Therapeutics	-$0.56	N/A	N/A	N/A	$2.50 million	N/A
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/7/2025	Q1 2025	TSVT 2seventy bio	-$0.10	$0.01	+$0.11	$0.01	$13.96 million	$22.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	25.86	25.86
MNPR Monopar Therapeutics	N/A	36.91	36.91
RPTX Repare Therapeutics	N/A	7.42	7.42
TSVT 2seventy bio	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
MNPR Monopar Therapeutics	1.83%
RPTX Repare Therapeutics	85.09%
TSVT 2seventy bio	93.90%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
MNPR Monopar Therapeutics	20.50%
RPTX Repare Therapeutics	11.50%
TSVT 2seventy bio	7.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable
RPTX Repare Therapeutics	180	42.89 million	37.96 million	Optionable
TSVT 2seventy bio	440	53.23 million	47.87 million	Optionable

RPTX, MNPR, TSVT, and AARD Headlines

Recent News About These Companies

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

May 7, 2025 | businesswire.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

April 16, 2025 | businesswire.com

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

March 27, 2025 | markets.businessinsider.com

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

March 25, 2025 | businesswire.com

Jessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

March 20, 2025 | insidertrades.com

2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why

March 17, 2025 | zacks.com

2seventy Bio price target lowered to $5 from $6 at Morgan Stanley

March 14, 2025 | markets.businessinsider.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

March 14, 2025 | businesswire.com

2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in Stock

March 14, 2025 | insidertrades.com

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

March 13, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT

March 12, 2025 | prnewswire.com

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders

March 11, 2025 | businesswire.com

2seventy bio accepts Bristol Myers’ takeover bid

March 11, 2025 | thepharmaletter.comT

Biotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition News

March 11, 2025 | investorideas.comI

TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders

March 11, 2025 | tmcnet.com

2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash

March 11, 2025 | markets.businessinsider.com

TSVT Up on Acquisition Agreement With BMY for $286 Million

March 11, 2025 | zacks.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

March 11, 2025 | prnewswire.com

Bristol Myers buys out cell therapy partner 2seventy bio

March 11, 2025 | endpts.comE

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

March 10, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, MNPR, TSVT, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$11.62 -0.34 (-2.84%)

As of 07/18/2025 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Monopar Therapeutics NASDAQ:MNPR

$46.48 -0.77 (-1.63%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$47.74 +1.26 (+2.70%)

As of 07/18/2025 06:00 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Repare Therapeutics NASDAQ:RPTX

$1.51 -0.01 (-0.66%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.51 0.00 (0.00%)

As of 07/18/2025 07:29 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

2seventy bio NASDAQ:TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time